JP2012149081A5 - - Google Patents

Download PDF

Info

Publication number
JP2012149081A5
JP2012149081A5 JP2012073369A JP2012073369A JP2012149081A5 JP 2012149081 A5 JP2012149081 A5 JP 2012149081A5 JP 2012073369 A JP2012073369 A JP 2012073369A JP 2012073369 A JP2012073369 A JP 2012073369A JP 2012149081 A5 JP2012149081 A5 JP 2012149081A5
Authority
JP
Japan
Prior art keywords
compound
disease
pharmaceutical composition
tissue
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012073369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012149081A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012149081A publication Critical patent/JP2012149081A/ja
Publication of JP2012149081A5 publication Critical patent/JP2012149081A5/ja
Withdrawn legal-status Critical Current

Links

JP2012073369A 2005-09-20 2012-03-28 Tdf関連化合物およびその類似体 Withdrawn JP2012149081A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71901405P 2005-09-20 2005-09-20
US60/719,014 2005-09-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008532384A Division JP2009508532A (ja) 2005-09-20 2006-09-20 Tdf関連化合物およびその類似体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014010456A Division JP2014132900A (ja) 2005-09-20 2014-01-23 Tdf関連化合物およびその類似体

Publications (2)

Publication Number Publication Date
JP2012149081A JP2012149081A (ja) 2012-08-09
JP2012149081A5 true JP2012149081A5 (https=) 2013-05-30

Family

ID=37889535

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008532384A Pending JP2009508532A (ja) 2005-09-20 2006-09-20 Tdf関連化合物およびその類似体
JP2012073369A Withdrawn JP2012149081A (ja) 2005-09-20 2012-03-28 Tdf関連化合物およびその類似体
JP2014010456A Pending JP2014132900A (ja) 2005-09-20 2014-01-23 Tdf関連化合物およびその類似体
JP2015206139A Pending JP2016047829A (ja) 2005-09-20 2015-10-20 Tdf関連化合物およびその類似体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008532384A Pending JP2009508532A (ja) 2005-09-20 2006-09-20 Tdf関連化合物およびその類似体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014010456A Pending JP2014132900A (ja) 2005-09-20 2014-01-23 Tdf関連化合物およびその類似体
JP2015206139A Pending JP2016047829A (ja) 2005-09-20 2015-10-20 Tdf関連化合物およびその類似体

Country Status (13)

Country Link
US (3) US8299212B2 (https=)
EP (3) EP2927241A1 (https=)
JP (4) JP2009508532A (https=)
AU (1) AU2006292147B2 (https=)
CA (2) CA2863125A1 (https=)
CY (1) CY1116742T1 (https=)
DK (1) DK2497780T3 (https=)
ES (1) ES2537527T3 (https=)
HU (1) HUE026634T2 (https=)
PL (1) PL2497780T3 (https=)
PT (1) PT2497780E (https=)
SI (1) SI2497780T1 (https=)
WO (1) WO2007035872A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299212B2 (en) 2005-09-20 2012-10-30 Thrasos Therapeutics, Inc. TDF-related compounds and analogs thereof, analogs and bioactive fragments
US8995742B1 (en) * 2009-11-10 2015-03-31 Us Synthetic Corporation Systems and methods for evaluation of a superabrasive material
EP2734220A4 (en) * 2011-07-19 2015-01-21 Thrasos Innovation Inc ANTIFIBROTIC PEPTIDES AND THEIR USE IN METHODS OF TREATING FIBROSIS-CHARACTERIZED DISEASES AND SUFFERING
ES2771324T3 (es) 2012-08-03 2020-07-06 Dana Farber Cancer Inst Inc Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
WO2015164800A2 (en) * 2014-04-24 2015-10-29 University Of Central Florida Research Foundation, Inc. Compositions and methods for modulating polarization of monocytes
US20160137714A1 (en) * 2014-11-12 2016-05-19 Thrasos Innovation, Inc. Peptides with enhanced stability and their use in methods for treating diseases
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
AU2019366366B2 (en) * 2018-10-22 2025-09-25 William D. Carlson Therapeutic combinations of TDFRPs and additional agents and methods of use
WO2022197855A1 (en) * 2021-03-16 2022-09-22 Therapeutics By Design, LLC Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis
EP4404950A4 (en) * 2021-09-22 2025-06-18 Therapeutics by Design, LLC CANCER TREATMENT METHODS
KR102749109B1 (ko) * 2021-11-04 2025-01-03 (주)케어젠 생리 활성을 갖는 펩타이드 및 그의 용도
EP4601667A1 (en) 2022-10-10 2025-08-20 Therapeutics by Design, LLC Tissue differentiation factor related polypeptides (tdfrps) for the treatment of myocardial injury
CN120838344B (zh) * 2025-09-19 2025-11-28 安徽天铁锂电新能源有限公司 粗碳酸锂提纯电池级碳酸锂的装置及其提纯方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4768523A (en) 1981-04-29 1988-09-06 Lifecore Biomedical, Inc. Hydrogel adhesive
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
GB8630273D0 (en) 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
US5092871A (en) 1987-03-13 1992-03-03 Brown University Research Foundation Electrically-charged nerve guidance channels
US5041126A (en) 1987-03-13 1991-08-20 Cook Incorporated Endovascular stent and delivery system
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5213580A (en) 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US4955892A (en) 1988-10-24 1990-09-11 Louisiana State University Neural cell adhesion protein nerve prosthesis
US5089606A (en) 1989-01-24 1992-02-18 Minnesota Mining And Manufacturing Company Water-insoluble polysaccharide hydrogel foam for medical applications
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
JPH085780B2 (ja) 1989-04-28 1996-01-24 呉羽化学工業株式会社 変形性関節症治療剤
AU633958B2 (en) 1989-07-25 1993-02-11 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5439446A (en) 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
US5052998A (en) 1990-04-04 1991-10-01 Zimmon David S Indwelling stent and method of use
US5064435A (en) 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
US5393788A (en) 1990-07-10 1995-02-28 Smithkline Beecham Corporation Phenylalkyl oxamides
WO1992013878A2 (en) 1991-02-07 1992-08-20 Board Of Trustees Of The University Of Illinois Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
WO1992015323A1 (en) 1991-03-11 1992-09-17 Creative Biomolecules, Inc. Protein-induced morphogenesis
US5147370A (en) 1991-06-12 1992-09-15 Mcnamara Thomas O Nitinol stent for hollow body conduits
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DE69233559T2 (de) 1991-08-30 2006-08-31 Curis, Inc., Cambridge Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
ATE192931T1 (de) 1991-08-30 2000-06-15 Creative Biomolecules Inc Morphogen-induzierte modulation von entzündlichen antworten
US5525519A (en) 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
US5176626A (en) 1992-01-15 1993-01-05 Wilson-Cook Medical, Inc. Indwelling stent
US5683448A (en) 1992-02-21 1997-11-04 Boston Scientific Technology, Inc. Intraluminal stent and graft
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
EP0653942B2 (en) 1992-07-31 2007-03-07 Curis, Inc. Morphogen-induced nerve regeneration and repair
ATE198049T1 (de) 1992-09-15 2000-12-15 Creative Biomolecules Inc Behandlung von magen- und darmgeschwüren mit morphogenen
ES2114073T3 (es) 1992-09-16 1998-05-16 Creative Biomolecules Inc Regeneracion del higado inducida por morfogenes.
EP1362913B1 (en) 1992-10-30 2006-01-25 The General Hospital Corporation Interaction trap system for isolating proteins
KR950704485A (ko) 1992-11-17 1995-11-20 로이드 제이. 오울드·에드워드 에이, 맥더모 2세 액티빈 리셉터-유사 키나제, 세린 트레오닌 키나제 도메인을 갖는 단백질 및 이들의 용도(activin receptor-like kinases, proteins having serine threonine kinase domains and their use)
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
US5579591A (en) 1993-06-29 1996-12-03 Limited Responsibility Company Frontier Footwear for patients of osteoarthritis of the knee
WO1995018856A1 (en) 1993-12-30 1995-07-13 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
AU702163B2 (en) 1994-04-29 1999-02-18 Creative Biomolecules, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
US5614609A (en) 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
US6210899B1 (en) 1994-11-04 2001-04-03 The Procter & Gamble Company Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor
US6306622B1 (en) 1994-11-04 2001-10-23 The Procter & Gamble Co. cDNA encoding a BMP type II receptor
US6281332B1 (en) 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5681274A (en) 1995-03-31 1997-10-28 Boston Scientific Corporation Variable length uretheral stent
US5569676A (en) 1995-05-24 1996-10-29 Diehl; Harry W. Method for the treatment of osteoarthritis
EP0845006A2 (en) 1995-08-14 1998-06-03 Creative Biomolecules, Inc. Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
US5989827A (en) 1995-11-14 1999-11-23 Abbott Laboratories Use of nuclear magnetic resonance to design ligands to target biomolecules
JP2000501744A (ja) * 1996-01-22 2000-02-15 クリエイティブ バイオモレキゥルズ,インコーポレーテッド モルホゲン類似体およびその製法
KR20000064752A (ko) 1996-03-22 2000-11-06 더 제네랄 호스피탈 코포레이션 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법
US6376199B1 (en) 1997-03-07 2002-04-23 The Hospital For Sick Children (Hsc) Methods to diagnose a required regulation of trophoblast invasion
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
US6111066A (en) 1997-09-02 2000-08-29 Martek Biosciences Corporation Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains
US6198281B1 (en) 1997-11-12 2001-03-06 The Research Foundation Of State University Of New York NMR spectroscopy of large proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP3561738B2 (ja) 1998-06-02 2004-09-02 株式会社リガク Bragg反射自動選出方法および装置並びに結晶方位自動決定方法およびシステム
US6800790B2 (en) 1998-07-24 2004-10-05 Carnegie Institution Of Washington Method for maintenance and propagation of germline stem cells using members of the TFG-β family of growth factors
JP2002524528A (ja) 1998-09-11 2002-08-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ヘッジホッグ様ポリペプチドによる肺組織の調節、およびそれに関する製剤および使用方法
US6329184B1 (en) 1998-12-18 2001-12-11 Pharmacia & Upjohn Ab Crystalline form of activated tartrate-resistant and purple acid phosphatase
US6444802B1 (en) 1999-09-30 2002-09-03 Millenium Pharmaceuticals, Inc. Human aminopeptidase
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6468346B2 (en) 1999-12-10 2002-10-22 Bsi Proteomics Corporation Applying x-ray topography and diffractometry to improve protein crystal growth
WO2001064238A2 (en) 2000-02-29 2001-09-07 Curis, Inc. Methods and compositions for regulating adipocytes
US6699278B2 (en) 2000-09-22 2004-03-02 Cordis Corporation Stent with optimal strength and radiopacity characteristics
ES2282163T3 (es) 2000-11-06 2007-10-16 Thrasos, Inc. Metodos de escrutinio de mimeticos de morfogenetica osea.
WO2002037313A2 (en) 2000-11-06 2002-05-10 Thrasos, Inc. Computer method and apparatus for classifying objects
US20040031066A9 (en) 2001-01-18 2004-02-12 Faustman Denise L. Mouse model for rheumatoid arthritis
US6679911B2 (en) 2001-03-01 2004-01-20 Cordis Corporation Flexible stent
EP1383867A2 (en) 2001-03-23 2004-01-28 Axordia Limited Stem cell differentiation
US6673106B2 (en) 2001-06-14 2004-01-06 Cordis Neurovascular, Inc. Intravascular stent device
US20030103959A1 (en) 2001-06-22 2003-06-05 Hughes Paul E. Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptor
WO2003106656A2 (en) * 2002-06-17 2003-12-24 Thrasos, Inc. Single domain tdf-related compounds and analogs thereof
AU2003276752A1 (en) * 2002-06-17 2003-12-31 Thrasos, Inc. Multiple domain tdf-related compounds and analogs thereof
JP4971149B2 (ja) * 2004-06-17 2012-07-11 スラソス セラピューティックス インコーポレーテッド Tdf関連化合物およびその類似体
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
US8299212B2 (en) * 2005-09-20 2012-10-30 Thrasos Therapeutics, Inc. TDF-related compounds and analogs thereof, analogs and bioactive fragments
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Similar Documents

Publication Publication Date Title
JP2012149081A5 (https=)
JP2014132900A5 (https=)
JP2012019788A5 (https=)
AU2022200142B2 (en) Crystals of anti-human PD-1 monoclonal antibodies
Terrell et al. Calcium’s role and signaling in aging muscle, cellular senescence, and mineral interactions
RU2421465C2 (ru) Антитела к рецептору igf-i
EP2900263B1 (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
JP6757712B2 (ja) 幹細胞増強治療法
AU2013209492B2 (en) Anti-CXCR3 antibodies
EP2033971A1 (de) Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
UA123862C2 (uk) Моноклональне антитіло, специфічне до гіперфосфорилованого тау-білка, і спосіб його застосування
KR101857310B1 (ko) 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체
TW201900682A (zh) 抗phf-tau抗體及其用途
UA125208C2 (uk) Антитіло до cd40
KR20130028050A (ko) 유방암을 치료하는 방법
EA029956B1 (ru) Кристаллы антител против склеростина и составы на их основе
EP2928494A1 (en) A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES
RU2015129720A (ru) Антитела к h7cr
JP2009508532A5 (https=)
KR20240058050A (ko) 아밀로이드 장애 치료를 위한 항체-펩티드 융합 단백질
JP5566374B2 (ja) 形質細胞の腫瘍性増殖をきたす疾患の治療薬
JP6999809B2 (ja) 免疫寛容を誘導する抗体、誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤治療法
JP2010540660A (ja) 哺乳類内の赤血球生成を刺激する新規の組成物および方法
JP2011173793A (ja) アセチルコリン受容体クラスター形成阻害活性を有するアグリンを特異的に認識する抗体並びに該抗体を含むアセチルコリン受容体クラスター形成能促進剤及び該抗体を充填したアセチルコリン受容体クラスター形成能を阻害するアグリン除去カラム
CN118063610A (zh) 靶向tim3的抗体及其核素标记物与应用